Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3517895 | 0.79 | IDO1 (0.41) | MAPTALDH1A1 | |
| SCHEMBL3520210 | 0.76 | PGR (0.62) | — | |
| SCHEMBL3519770 | 0.72 | PGR (0.53) | TP53MAPTPOLBNQO2LMNA | |
| SCHEMBL29891547 | 0.72 | PGR (0.53) | TP53MAPTPOLBNQO2LMNA | |
| SCHEMBL6069995 | 0.70 | NOS3 (0.45) | TP53MAPTPOLBNQO2LMNA | |
| SCHEMBL25682397 | 0.70 | TP53 (0.49) | TP53MAPTPOLBNQO2LMNA | |
| SCHEMBL14438188 | 0.68 | NQO2 (0.50) | TP53MAPTPOLBNQO2LMNA | |
| SCHEMBL2989569 | 0.68 | TP53 (0.62) | TP53MAPTPOLBNQO2LMNA | |
| SCHEMBL31694121 | 0.68 | TP53 (0.48) | TP53MAPTPOLBNQO2LMNA | |
| SCHEMBL28327834 | 0.67 | NQO2 (0.46) | TP53MAPTPOLBNQO2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645761-B2 | Indoline derivatives | WYETH (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070259944-A1 | Indoline derivatives | WYETH (US) | 2007-11-08 | — | — | US | disclosed |
| US-7253203-B2 | Indoline derivatives | WYETH (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1175398-B1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | WYETH CORP (US) | 2007-07-11 | — | — | EP | disclosed |
| US-7084168-B2 | Indoline derivatives | WYETH (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060160882-A1 | Indoline derivatives | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| US-20030220388-A1 | Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents | WYETH | 2003-11-27 | — | — | US | disclosed |
| US-6608068-B2 | Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents | WYETH | 2003-08-19 | — | — | US | disclosed |
| US-6544970-B2 | Administering in a first phase of a progestational agent (levonorgestrel or ethinylestradiol) and in a second phase an antiprogestin that is an indolinone derivative, especially a 3-spiroalkylene derivative | WYETH | 2003-04-08 | — | — | US | disclosed |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2003-03-13 | — | — | US | disclosed |
| US-6462032-B1 | Cyclic regimens utilizing indoline derivatives | WYETH | 2002-10-08 | — | — | US | disclosed |
| US-20020086874-A1 | Indoline derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-07-04 | — | — | US | disclosed |
| US-6391907-B1 | ANTICANCER AGENTS; CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1175398-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | American Home Products Corporation (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066556-A1 | INDOLINE DERIVATIVES AS PROGESTERONE ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259944-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | TP53 273/4885MAPT 2501/4885POLB 4140/4885 |
| US-20020086874-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | TP53 263/4885MAPT 2508/4885POLB 4042/4885 |
| US-20060160882-A1 | Indoline derivatives | PGR, GNRHR, PRLHR | TP53 273/4885MAPT 2501/4885POLB 4140/4885 |
| US-20030220388-A1 | Amides such as 5-(3-Nitrophenyl)-1,3-dihydro-indol-2-one, used as antiprogesterones, contraceptives, for hormone replacement therapy during menopause and as anticarcinogenic agents | PGR, CYP19A1, PGRMC1 | TP53 342/4885MAPT 3746/4885POLB 3154/4885 |
| US-20030050288-A1 | Cyclic regimens utilizing indoline derivatives | PRLHR, GNRHR, BRCA1 | TP53 431/4885MAPT 4533/4885POLB 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.